2023

  •  ALA-1300 has received a notice of allowance from The National Office of Intellectual Property of Vietnam (NOIP) after the examination. (Patent Application No. 1-2020-06145)

2022

  • ALA-1000 received notice of patent allowance from National Institute of Industrial Property Institute (INAPI), Chile on August 10, Application No. 624-2019 
  • ALA-1000 received notice of patent allowance from  European Patent Office (EPO) on May 12 , Application No. 17850245.6
  • ALA-1000 received notice of patent allowance from Director de Invenciones y Nuevas Tecnologías INDECOPI on May 12, Application No. 000487-2019/DIN
  • ALA-1000 received notice of patent allowance from Intellectual Property Office of India on May 6, Application No. 201947006642
  • ALA-1000 received notice of patent allowance from Intellectual Property Office of Singapore (IPOS) on April 21, Application No. 11201901294Q
  • Alar announces Significant Progress on Developing long-acting Buprenorphine
    Injectable ALA-1000 on January 13

2021

  • ALA-1000 received notice of patent allowance from Directorate General of Intellectual Property (DGIP) of Indonesia on November 30, Application No. P00201902139
  • Alar announced results from ALA-1000 Single Ascending Dose Study in Opioid Dependent Patients on November 9
  • ALA-1000 received notice of patent allowance from Intellectual Property Office of Vietnam on October 29, Application No. 1-2019-01258
  • Successful End-of-Phase 2 Meeting with US FDA for ALA-1000 for the Treatment of Opioid Use Disorder on October 28
  • ALA-1000 received notice of patent allowance from Taiwan Intellectual Property Office (TIPO) on September 3, Application No. 106131215
  • ALA-1000 received notice of patent allowance from South Africa-Companies and Intellectual Property Commission Department of Trade and Industry (CIPC) on August 25, Application No. 201900890
  • ALA-1000 received notice of patent allowance from Japan Patent Office (JPO) on August 3,  Application No. 特願2019-535434
  • ALA-1000 received notice of patent allowance from Innovation, Science and Economic Development Canada (ISED) on May 10, Application No.3,033,046
  • ALA-1000 received notice of patent allowance from the IP New Zealand on April 30. Patent No. 750367
  • ALA-1000 received notice of allowance for patent registration from Korean Intellectual Property Office on April 16 (Application No. 10-2019-7009185)
  • ALA-1000 received Decision of Grant from Federal Service for Intellectual Property (ROSPATENT) on April 12 (Application No. 2019102895)

2020

  • Listed on Taipei Exchange Market in Taiwan on September 23. Traded on October 5
  • ALA-1000 received notice of patent allowance from the IP Australia
  • ALA-3000 completed pre-IND Meeting with US FDA
  • ALA-1000 received notice of patent allowance from the Mexican Institute of Industrial Property (IMPI)
  • Approved to be a public offering company on June 3.  Stock Code: 6785
  • ALA-1000 received notice of patent allowance from USPTO
  • ALA-1000 was approved by Ministry of Economic Affairs : A+ Industrial Innovation R&D Program (fast track)

2019

  • Approved by the Ministry of Economic Affairs as a Biotech Pharmaceutical company

  • ALA-1000 received US FDA IND approval

  • Approved to be located in Central Science Park

2017

  • ALA-1000 was approved by Ministry of Economic Affairs：A+ Industrial Innovation R&D Program－Industrial Technology Foresight Research Program

2016

  • Alar Pharmaceuticals Inc. was founded

Add Your Heading Text Here